TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01725906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empirical therapy
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotypic resistance guided therapy
Description: 1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
Study: NCT02217839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173+Octreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173 Placebo+Octreotide Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide+DG3173 Placebo
Study: NCT03074409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: self-administration of oxytocin (nasal spray)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: self-administration of placebo (nasal spray)
Study: NCT02772601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Study: NCT01723098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study: NCT03058120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deferral of admission for stress test
Description: Early discharge; admission and stress test are deferred.
Study: NCT04862715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl (sodium chloride 0.9%)
Description: Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
Study: NCT01319669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human thrombopoietin
Description: Recombinant human thrombopoietin injection in 15000U/ml/amp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: Recombinant human thrombopoietin injection in 15000U/ml/amp.
Study: NCT00823862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Intramuscular (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: oral, 2 times per day, for 2 months
Study: NCT04027855

Intervention type: PROCEDURE
Group type: OTHER
Intervention: collection of peripheral blood mononuclear cells from healthy volunteers
Description: 1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis.
Study: NCT02021201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia will be treated for 10 weeks treatment with risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia will be treated for 10 weeks treatment with risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Patients with schizophrenia will be treated for 10 weeks treatment with serindole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Patients with schizophrenia will be treated for 10 weeks treatment with serindole
Study: NCT04471519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152A - Phase I
Description: 0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152B - Phase I
Description: 0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152C - Phase I
Description: 0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Phase I
Description: 0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152A - Phase II
Description: 0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV152B - Phase II
Description: 0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
Study: NCT03057093

Intervention type: OTHER
Intervention: Non interventional study
Description: retrospective noninterventional study

Intervention type: OTHER
Intervention: Non interventional study
Description: retrospective noninterventional study
Study: NCT00837252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Participants received 5mg of oral finasteride daily for three months.
Study: NCT04239001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
Study: NCT03741088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VORTX Rx treatment
Description: Cavitation-based cellular destruction using focused ultrasound
Study: NCT01908426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT04445935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin Injection
Description: The patients will receive iv Bivalirudin according to the institutional HIT protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: This group will receive standard anticoagulation with LMWH/UFH
Study: NCT01853826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Patients will receive afatinib once daily
Study: NCT00262860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02741128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0.9%) vaccine group
Description: 0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
Study: NCT02906514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)
Description: 1000mL used for cardiopulmonary bypass priming

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% (Fresenius)
Description: 1000mL used for cardiopulmonary bypass priming
Study: NCT04406298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small quantity paracentesis
Description: Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis
Description: Large Volume Paracentesis \> 5litres
Study: NCT01102686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
Study: NCT02743585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filmarray Blood Culture ID (BCID) panel
Description: The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in \< 1 - 1.5 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rosco Diagnostica ESBL/carbapenemase screen kit
Description: These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
Study: NCT04614311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide 20 MG/ML
Description: JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
Study: NCT04085575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acide Tranexamique
Description: Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acide Tranexamique
Description: Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
Study: NCT04426929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise therapy
Description: Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Chain Exercise Group
Description: An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Based Exercise Group
Description: Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
Study: NCT01017484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH, Control
Description: controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH, Control
Description: controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
Study: NCT04149912

Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study: NCT00699036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avandia
Description: 4 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avandia
Description: 4 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avandia
Description: 4 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 500 mg twice daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan 50 mg once daily
Study: NCT03977792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOR15001L7
Description: BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docosanol Cream 10%
Description: Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
Study: NCT02161770

Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablet dosing
Description: Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablet dosing
Description: Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablet dosing
Description: Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291 pharmacokinetic parameters.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291 pharmacokinetic parameters.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291 pharmacokinetic parameters.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
Study: NCT01405768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate buffered lidocaine
Description: 8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-buffered lidocaine
Study: NCT00265564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Seeking Safety integrated into std outpatient SUD care
Description: The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard outpatient SUD care
Description: Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence.
Study: NCT04823403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~* (D1) Starting dose : 50 mg; n=3 to 6~* (D2) 2nd dose-level : 100 mg; n=3 to 6~* (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)
Study: NCT04175249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pizza meal challenge
Description: Vegetarian pizza containing 10 grams of salt
Study: NCT01557153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
Study: NCT02130921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Address Drug Use and HIV in Vietnam
Description: Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change.
Study: NCT03647488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib 400 mg (tablets) orally taken twice daily
Study: NCT02038816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox + Azacitidine
Description: Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
Study: NCT03647488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib 400 mg (tablets) orally taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab 400 mg via intravenous infusion once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab 400 mg via intravenous infusion once every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
Study: NCT03046108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Morton neuroma
Description: Introduction of a needle based in anatomical landmark
Study: NCT02038816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
Study: NCT03224130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Phone Call
Description: We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.